Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: A multitude of factors may influence fatigue in psoriasis and psoriatic arthritis (PsA); however, their individual fatigue components have not been thoroughly examined.
Objectives: To explore characteristics of fatigue and its potential drivers in a cohort of patients with psoriasis with or without PsA.
Methods: Adults with psoriasis and a nonpsoriasis control group completed the Multidimensional Fatigue Inventory-20 questionnaire. Patients with psoriasis also reported joint pain intensity, pruritus, skin pain, and sleep problems using a numerical rating scale. Linear regression models were applied to continuous outcomes, and beta coefficients (β) for the slopes were estimated with 95% confidence intervals (CIs).
Results: Among 2741 adults with psoriasis (of which 593 also had PsA) and 3788 controls, the impact on total fatigue was greatest for PsA (β = 5.22; 95% CI, 3.55-6.90), followed by psoriasis (β = 2.10; 95% CI, 0.96-3.25), compared with the general population (P < .0001). Among patients with psoriasis with or without PsA, increasing joint pain intensity was associated with overall fatigue (β = 2.23 [95% CI, 2.03-2.44] for each 1-point increase in joint pain numerical rating scale score).
Limitations: We lacked information on the effect of pharmacotherapy.
Conclusions: These findings highlight the importance of a symptom-based approach when treating psoriasis, rather than focusing on objective severity measures alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2024.02.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFRole of SLC16A10 in Psoriasis Through the Regulation of Arachidonic Acid Metabolism in Keratinocytes.
Adv Sci (Weinh)
September 2025
Department of Dermatology, Air Force Medical Center, PLA, Beijing, 100142, China.
Psoriasis is an inflammatory dermatological condition challenging to treat and prone to recurrence. The pathogenesis of psoriasis is closely associated with metabolic disorders, while therapies targeting the dysregulated metabolism in psoriasis remain limited. Therefore, exploring the pathogenesis of psoriasis and identifying potential metabolic therapeutic targets is imperative.
View Article and Find Full Text PDFBeginning of the End (BOTE) Sign in the Setting of Recurrent Molluscum Contagiosum in a Child.
Cureus
August 2025
Pathology, Dermatology, University of Mississippi Medical Center, Jackson, USA.
Molluscum contagiosum (MC) is a common cutaneous viral infection predominantly affecting children. In this report, we present the case of a five-year-old male with recurrent MC who developed the beginning of the end (BOTE) sign, reflecting an inflammatory response that correlates with imminent lesion resolution. The patient's lesions were monitored without further intervention following the appearance of the BOTE sign, and complete resolution was documented in roughly two months.
View Article and Find Full Text PDFEffectiveness and Safety of Risankizumab for Psoriasis in a Liver Transplant Patient With Recurrent Metastatic Hepatocellular Carcinoma.
Cureus
August 2025
Dermatology, Hôpital Privé Francheville, Perigueux, FRA.
Risankizumab (RZB) is a humanized monoclonal antibody that selectively targets interleukin-23 (IL-23). It has proven particularly effective in treating psoriasis, a common chronic inflammatory skin disease. However, its use remains poorly documented in certain populations, including patients with a history of solid organ transplantation or recent/active malignancy.
View Article and Find Full Text PDFSyphilis Uveitis: A Case of Occam's Razor, Hickam's Dictum, and Crabtree's Bludgeon.
Cureus
August 2025
Ophthalmology, Henry Ford Health System, Detroit, USA.
This report discusses a case of diagnosing neurosyphilis in a non-classical presentation with confounding test results needing a deliberate and multidisciplinary diagnostic approach. A 38-year-old immunocompetent male presented with uveitis and a skin rash. Although serology was positive for syphilis (rapid plasma reagin 1:128), it was also positive for tuberculosis, and a dermatology consult identified the rash as psoriasis, creating a complex diagnostic picture.
View Article and Find Full Text PDF